Hidradenitis suppurativa: redirecting a life trajectory

Linked Article: Howells et al. Br J Dermatol 2021; 185:921–934.

Saved in:
Bibliographic Details
Published inBritish journal of dermatology (1951) Vol. 185; no. 5; p. 878
Main Authors Hsiao, J., Shi, V.
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.11.2021
Subjects
Hidradenitis Suppurativa - epidemiology
Humans
Quality of Life
Severity of Illness Index
Online AccessGet full text

Cover

More Information
Summary:Linked Article: Howells et al. Br J Dermatol 2021; 185:921–934.
Bibliography:Conflicts of interest: J.H. is on the board of directors for the Hidradenitis Suppurativa Foundation, and is a speaker for AbbVie and consultant for Novartis. V.S. is on the board of directors for the Hidradenitis Suppurativa Foundation, and has served as an advisor, investigator and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt’s Bees, Dermira, Eli Lilly, Novartis, Pfizer, Incyte, Galderma, LEO Pharma, Sun Pharma, Menlo Therapeutics, gpskin, TARGET‐DERM, Kiniksa and Skin Actives Scientific. There was no financial transaction for the preparation of this manuscript.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.20696